NCCN Patient Webinar: Small Cell Lung Cancer

Описание к видео NCCN Patient Webinar: Small Cell Lung Cancer

Join experts as they provide information and answer questions about small cell lung cancer to help patients and caregivers compare, discuss, and select treatment options with their doctor. See list below for topics discussed. Please note that this is a not an accredited activity.

Topics Discussed:
00:00 - Welcome and Introductions
02:09 - Cancer Staging
09:58 - Treatment
20:34 - Supportive Care to Improve Quality of Life
41:33 - New Treatments
47:14 - Clinical Trials
52:00 - Clinical Trials and Informational Sources Available to the Patient
1:02:07 - Q & A
1:20:26 - Closing Remarks

Question and Answer Session:
1:02:15 - What are some concerns about clinical trials?
1:03:35 - What level of fever do you ask patients to report? Do they call the office or go to the ER?
1:04:40 - Do you recommend prophylactic medications to prevent or manage neutropenia?
1:06:29 - How long after stopping immunotherapies should people monitor or report side effects?
1:08:00 - Who would you call regarding fatigue issues?
1:08:34 - Are there any immunotherapies available to people that have stable microsatellites and a low tumor mutational burden? Can these be successful?
1:09:42 - Is Lurbinectedin available in the EU?
1:10:03 - Biomarker testing is a standard of care in non-small cell lung cancer, but I've heard very little in small cell lung cancer. Is this something that is showing promise? If not, why not?
1:11:33 - How long after the last session of chemotherapy does it typically take for a CT scan to be performed to assess how the treatment performed?
1:12:36 - How long is immunotherapy recommended for to determine its effectiveness?
1:14:04 - What is meant by 'small cell lung cancer being a neuroendocrine tumor'? What is the mechanism or make up of the tumor to be given this classification?
1:15:56 - What are the characteristics for the 3% that survive 1 to 5 years?
1:16:44 - Are paraneoplastic syndromes checked for with bloodwork or symptoms only?
1:17:46 - Do you recommended 4 or 6 cycles for first line chemotherapy immunotherapy?
1:18:10 - When would clinical trials be recommended or introduced to a new patient that was recently diagnosed?
1:18:58 - Can an extensive stage small cell lung cancer patient receive preventative brain radiation?

The Patient Webinars: Small Cell Lung Cancer occurred in January 2022. This informational program was created in conjunction with the newly published NCCN Guidelines for Patients® for Small Cell Lung Cancer. (https://www.nccn.org/patientresources...)

The NCCN Guidelines for Patients (http://nccn.org/patientguidelines) are available to read and download for free online and via the NCCN Patient Guides for Cancer mobile app. Printed editions can be ordered from Amazon.com for a small fee.

NCCN Guidelines for Patients DO NOT replace the expertise and clinical judgment of the clinician.

Supporters:
This webinar is supported through the NCCN Foundation® and by a contribution from our corporate supporter: AstraZeneca.
________________________________________________________________
About NCCN Foundation®:
NCCN FOUNDATION® is a 501(c)3 organization founded by the National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education—to empower people living with cancer and advance oncology innovation. For more information or to make a donation, visit http://www.nccn.org/patients/foundation
________________________________________________________________
About NCCN:
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. Visit https://www.nccn.org/ for more information.

Subscribe to our channel for the latest in cancer care: https://www.youtube.com/c/NCCNvideo?s...

Connect with us!
Twitter:   / nccn  
LinkedIn:   / nccn  
Facebook:   / nccnorg  
Instagram:   / nccnorg  

Комментарии

Информация по комментариям в разработке